Medway Maritime NHS Foundation Trust, Windmill Rd, Kent ME7 5NY

Project Name: Lipid Optimisation service - Medway Maritime NHS Foundation Trust

Project Summary:

The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimisation of patients with atherosclerotic cardiovascular disease (ASCVD) who are at high risk of cardiovascular events and who are not achieving lipid levels as specified in national and/or local guidance, with a particular focus on the transition of care between secondary and primary care, in response to the needs of the CW Partner. The intention is to increase secondary care initiation of medicines with the repatriation of relevant patients back to primary care for continued care. 

The secondary objective is to reduce the current backlog of patients waiting to be seen by Medway Maritime lipid service by implementing a local secondary care led secondary prevention clinic, focusing on supporting the discharge and onward management of secondary prevention patients, including first dose medicine optimisation, and subsequent transfer to primary care setting. The Kent and Medway Integrated Care Board (ICB) will be engaged for the general handover of care to primary care. The CVD lead Kent and Medway ICB working alongside a multi-disciplinary team will be involved to ensure appropriate transfer to primary care.

This will be achieved by the funding for an additional Lead Lipid Nurse Specialist Band 7 to develop a new Lipid Optimisation service within the trust.

Planned Milestones:

Expected Benefits:

ANTICIPATED BENEFITS FOR PATIENTS

• Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.   
• Enhanced experience around ASCVD with ongoing management of the condition.   
• Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events  
• The additional capacity will provide additional time and support from PCN HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up. Thus, leveling health inequalities within the PCN. 

ANTICIPATED BENEFITS FOR THE ORGANISATION(S)

• Increased proportion of secondary care ASCVD patients undergoing lipid optimisation
• Increased proportion of ASCVD patients receiving expert and timely review 
• Reduction in ASCVD events in patients who have received a review and medicines optimisation, and leading to fewer admissions to secondary care
• Increased proportion of patients receiving guideline-directed pharmacotherapy  
• Support aligned to NHS Long Term Plan and CVDPREVENT

ANTICIPATED BENEFITS FOR NOVARTIS

• Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicines, where appropriate
• Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities    
• Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation.  

Start Date & Duration: October 2024 for 15 months

UK | September 2024 | FA-11280753